Mark K. Ferguson to Survival Rate
This is a "connection" page, showing publications Mark K. Ferguson has written about Survival Rate.
Connection Strength
0.713
-
A Morphomic Index Is an Independent Predictor of Survival After Lung Cancer Resection. Ann Thorac Surg. 2020 03; 109(3):873-878.
Score: 0.134
-
Does Race Influence Risk Assessment and Recommendations for Lung Resection? A Randomized Trial. Ann Thorac Surg. 2018 10; 106(4):1013-1017.
Score: 0.120
-
Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg. 2003 Dec; 76(6):1782-8.
Score: 0.044
-
Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1935-42.
Score: 0.044
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.038
-
Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000 Aug; 18(2):156-61.
Score: 0.035
-
Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.
Score: 0.034
-
Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2000 Jan; 69(1):245-9; discussion 249-50.
Score: 0.034
-
Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg. 1999 Mar; 117(3):581-6; discussion 586-7.
Score: 0.032
-
Esophageal perforation and caustic injury: management of perforated esophageal cancer. Dis Esophagus. 1997 Apr; 10(2):90-4.
Score: 0.028
-
Current results of therapy for esophageal perforation. Am J Surg. 1995 Jun; 169(6):615-7.
Score: 0.024
-
Thoracic Revised Cardiac Risk Index Is Associated With Prognosis After Resection for Stage I Lung Cancer. Ann Thorac Surg. 2015 Jul; 100(1):195-200.
Score: 0.024
-
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1995 Mar; 2(2):101-6.
Score: 0.024
-
Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013 Jul; 8(7):915-22.
Score: 0.021
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
Score: 0.021
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.018
-
Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990 Aug; 8(8):1402-7.
Score: 0.017
-
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol. 1998 Jun; 16(6):2157-63.
Score: 0.008
-
Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol. 1998 Jun; 9(6):647-51.
Score: 0.008
-
Management of giant paraesophageal hernia. Dis Esophagus. 1997 Jan; 10(1):47-50.
Score: 0.007